Les cancers biliaires à l’ère des thérapies ciblées (notice n° 665213)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02857cam a2200349 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121193859.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Colle, Raphael |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Les cancers biliaires à l’ère des thérapies ciblées |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2023.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 61 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | The AFEF and ESMO 2022 symposia have outlined one of the three recent developments in the management of biliary tract cancers, along with the definition of standard chemotherapies and the entry of immune checkpoint inhibitors into the therapeutic arsenal, namely, the contribution of precision medicine. Biliary tract cancers, and particularly intrahepatic cholangiocarcinomas, are rich in targetable molecular alterations. This fact imposes a more marked attention to the quantity and quality of tumor samples and a multidisciplinary work with samplers, pathologists and molecular biologists in order to advance jointly and as soon as possible in the diagnosis and the molecular characterization of these cancers. Among the targets of interest, IDH1 mutations and FGFR2 fusions are the more frequent ones, for which inhibitors are already available. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Les symposiums de l’AFEF et de l’ESMO 2022 ont permis de faire le point sur l’une des trois récentes évolutions de la prise en charge des cancers biliaires, aux côtés de l’instauration de standards de chimiothérapie et de l’entrée des inhibiteurs de checkpoints immunitaires dans l’arsenal thérapeutique, qu’est la médecine de précision. Les cancers biliaires et particulièrement les cholangiocarcinomes intra-hépatiques sont riches en altérations moléculaires ciblables. Ce fait impose une attention plus marquée à la quantité et à la qualité des prélèvements tumoraux et un travail pluridisciplinaire avec les préleveurs, les anatomopathologistes et les biologistes moléculaires afin d’avancer conjointement et dans les meilleurs délais dans le diagnostic et la caractérisation moléculaire de ces cancers. Parmi les cibles d’intérêt, les plus fréquentes sont les mutations de IDH1 et les fusions de FGFR2, pour lesquels des inhibiteurs sont d’ores et déjà disponibles. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | FGFR2 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | fusion |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | mutation |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | thérapies ciblées |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancers biliaires |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | IDH1 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cholangiocarcinome |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | targeted therapies |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | FGFR2 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | fusion |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | mutation |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cholangiocarcinoma |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Biliary tract cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | IDH1 |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Malka, David |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 30 | N° Supp 2 | 2023-03-15 | p. 4-9 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2023-HS2-page-4?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2023-HS2-page-4?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux